CA3198258A1 - Medicament pour soulager la douleur neuropathique - Google Patents

Medicament pour soulager la douleur neuropathique

Info

Publication number
CA3198258A1
CA3198258A1 CA3198258A CA3198258A CA3198258A1 CA 3198258 A1 CA3198258 A1 CA 3198258A1 CA 3198258 A CA3198258 A CA 3198258A CA 3198258 A CA3198258 A CA 3198258A CA 3198258 A1 CA3198258 A1 CA 3198258A1
Authority
CA
Canada
Prior art keywords
receptor
hydroxymethyl
carboxamide
hydroxy
tetrahydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198258A
Other languages
English (en)
Inventor
Yosuke Imai
Hikaru Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3198258A1 publication Critical patent/CA3198258A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé qui atténue la fonction des récepteurs P2X7 afin de traiter la douleur neuropathique humaine.
CA3198258A 2020-11-30 2021-11-26 Medicament pour soulager la douleur neuropathique Pending CA3198258A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020199206 2020-11-30
JP2020-199206 2020-11-30
PCT/JP2021/043375 WO2022114122A1 (fr) 2020-11-30 2021-11-26 Médicament pour soulager la douleur neuropathique

Publications (1)

Publication Number Publication Date
CA3198258A1 true CA3198258A1 (fr) 2022-06-02

Family

ID=81755628

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198258A Pending CA3198258A1 (fr) 2020-11-30 2021-11-26 Medicament pour soulager la douleur neuropathique

Country Status (11)

Country Link
US (1) US20240009180A1 (fr)
EP (1) EP4272758A1 (fr)
JP (1) JPWO2022114122A1 (fr)
KR (1) KR20230096055A (fr)
CN (1) CN116782901A (fr)
AU (1) AU2021389409A1 (fr)
CA (1) CA3198258A1 (fr)
IL (1) IL302972A (fr)
MX (1) MX2023006289A (fr)
TW (1) TW202237111A (fr)
WO (1) WO2022114122A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507964B (zh) 2012-06-01 2020-05-15 埃博灵克斯股份有限公司 P2x7受体拮抗剂和激动剂
JP6301920B2 (ja) 2013-05-27 2018-03-28 国立大学法人 岡山大学 疼痛治療薬
PT3609868T (pt) 2017-03-13 2023-12-18 Raqualia Pharma Inc Derivados de tetra-hidroquinolina como antagonistas do recetor p2x7
EP3398941A1 (fr) 2017-05-03 2018-11-07 AXXAM S.p.A. Antagonistes de p2x7 hétérocycliques
JP7311944B2 (ja) 2018-04-16 2023-07-20 塩野義製薬株式会社 二環性含窒素複素環誘導体を含有する医薬組成物
JP2019182806A (ja) 2018-04-16 2019-10-24 塩野義製薬株式会社 二環性複素環誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
CN116782901A (zh) 2023-09-19
KR20230096055A (ko) 2023-06-29
MX2023006289A (es) 2023-07-31
WO2022114122A1 (fr) 2022-06-02
AU2021389409A1 (en) 2023-06-22
EP4272758A1 (fr) 2023-11-08
TW202237111A (zh) 2022-10-01
US20240009180A1 (en) 2024-01-11
IL302972A (en) 2023-07-01
JPWO2022114122A1 (fr) 2022-06-02

Similar Documents

Publication Publication Date Title
Banerjee et al. Does serotonin deficit mediate susceptibility to ADHD?
Thomas et al. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications
JP6895252B2 (ja) 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
KR20100127799A (ko) 세로토닌 운반체 유전자 및 알콜중독의 치료
Natera-de Benito et al. Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations
EA017915B1 (ru) Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
EP3846810B1 (fr) Dosage nocturne chronique de lasmiditan pour la prévention de la migraine
Donovan et al. Disrupted choline clearance and sustained acetylcholine release in vivo by a common choline transporter coding variant associated with poor attentional control in humans
EP3156054A1 (fr) Médicament pour la prévention et/ou le traitement de maladies induites par le stress
US20240009180A1 (en) Medicine for alleviating neuropathic pain
JP7088628B2 (ja) うつ病や急性ストレス障害の診断バイオマーカー及び治療又は予防用組成物
KR20230128037A (ko) Er형 미스센스 돌연변이를 갖는 환자에서, c형 니만픽병의 치료를 위한 아리모클로몰
JP2024026905A (ja) てんかん治療剤
EP3233825B1 (fr) Dérivés de diarylméthylidène pipéridine et leur utilisation comme agonistes du récepteur opioïde delta
WO2023135978A1 (fr) Médicament pour traiter les effets secondaires d'une infection au nouveau coronavirus
EP3860607B1 (fr) Composé (8ar,12as,13as)-5,8,8a,9,10,11,12,12a,13,13a-décahydro-3-méthoxy-12-(éthylsulfonyl)-6h-isoquino [2,1-g] [1,6] naphthyridine pour une utilisation dans le traitement de psychoses
US20240068035A1 (en) Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
WO2023078807A1 (fr) Inhibiteur de hdac de classe iia et decitabine pour traiter la myopathie
TW202307217A (zh) 用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法
WO2020176807A1 (fr) Méthodes de traitement de la douleur du nerf trijumeau
Meng et al. 109P Preserve sense by antisense–a novel allele-specific antisense oligonucleotide therapy for SPTLC1-related hereditary sensory neuropathy
Barkhuizen Genetic and perinatal risk factors for movement disorders
JP2024537981A (ja) 筋萎縮性側索硬化症を治療する方法
CA3236338A1 (fr) Methode de traitement de la sclerose laterale amyotrophique et regime posologique associe

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231228